anti-KRAS

N/A

Report date: 2025/01/26 19:13:08

Base Information

Drug Nameanti-KRAS
Drug Alias NameKRAS siRNA plasmid-based in vivo self-assembled exosomes (Micromedmark Biotech)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNABiologics > Exosomes
Mechanisms of ActionV-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog inhibitors
TargetsGTPase KRas
Therapy Area/IndicationsLung NeoplasmsPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesJiangsu Mingma Biological Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJiangsu Mingma Biological Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsLung NeoplasmsPancreatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A